Literature DB >> 23152513

Whole-genome sequencing of the Akata and Mutu Epstein-Barr virus strains.

Zhen Lin1, Xia Wang, Michael J Strong, Monica Concha, Melody Baddoo, Guorong Xu, Carl Baribault, Claire Fewell, William Hulme, Dale Hedges, Christopher M Taylor, Erik K Flemington.   

Abstract

Using a simple viral genome enrichment approach, we report the de novo assembly of the Akata and Mutu Epstein-Barr virus (EBV) genomes from a single lane of next-generation sequencing (NGS) reads. The Akata and Mutu viral genomes are type I EBV strains of approximately 171 kb in length. Evidence for genome heterogeneity was found for the Akata but not for the Mutu strain. A comparative analysis of Akata with another four completely sequenced EBV strains, B95-8/Raji, AG876, Mutu, and GD1, demonstrated that the Akata strain is most closely related to the GD1 strain and exhibits the greatest divergence from the type II strain, AG876. A global comparison of latent and lytic gene sequences showed that the four latency genes, EBNA2, EBNA3A, EBNA3B, and EBNA3C, are uniquely defining of type I and type II strain differences. Within type I strains, LMP1, the latency gene, is among the most divergent of all EBV genes, with three insertion or deletion loci in its CTAR2 and CTAR3 signaling domains. Analysis of the BHLF1 and LF3 genes showed that the reading frames identified in the B95-8/Raji genome are not conserved in Akata (or Mutu, for BHLF1), suggesting a primarily non-protein-coding function in EBV's life cycle. The Akata and Mutu viral-genome sequences should be a useful resource for homology-based functional prediction and for molecular studies, such as PCR, RNA-seq, recombineering, and transcriptome studies. As an illustration, we identified novel RNA-editing events in ebv-miR-BART6 antisense transcripts using the Akata and Mutu reference genomes.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23152513      PMCID: PMC3554088          DOI: 10.1128/JVI.02517-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  28 in total

1.  Sequence and transcription of Raji Epstein-Barr virus DNA spanning the B95-8 deletion region.

Authors:  B D Parker; A Bankier; S Satchwell; B Barrell; P J Farrell
Journal:  Virology       Date:  1990-11       Impact factor: 3.616

2.  Different Epstein-Barr virus-B cell interactions in phenotypically distinct clones of a Burkitt's lymphoma cell line.

Authors:  C D Gregory; M Rowe; A B Rickinson
Journal:  J Gen Virol       Date:  1990-07       Impact factor: 3.891

3.  DNA sequence and expression of the B95-8 Epstein-Barr virus genome.

Authors:  R Baer; A T Bankier; M D Biggin; P L Deininger; P J Farrell; T J Gibson; G Hatfull; G S Hudson; S C Satchwell; C Séguin
Journal:  Nature       Date:  1984 Jul 19-25       Impact factor: 49.962

4.  Sequence variation in the Epstein-Barr virus latent membrane protein 1.

Authors:  W E Miller; R H Edwards; D M Walling; N Raab-Traub
Journal:  J Gen Virol       Date:  1994-10       Impact factor: 3.891

5.  Cross-linking of cell surface immunoglobulins induces Epstein-Barr virus in Burkitt lymphoma lines.

Authors:  K Takada
Journal:  Int J Cancer       Date:  1984-01-15       Impact factor: 7.396

6.  Epstein-Barr virus types 1 and 2 differ in their EBNA-3A, EBNA-3B, and EBNA-3C genes.

Authors:  J Sample; L Young; B Martin; T Chatman; E Kieff; A Rickinson; E Kieff
Journal:  J Virol       Date:  1990-09       Impact factor: 5.103

7.  Epstein-Barr virus types 1 and 2 have nearly identical LMP-1 transforming genes.

Authors:  J Sample; E F Kieff; E D Kieff
Journal:  J Gen Virol       Date:  1994-10       Impact factor: 3.891

8.  Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration.

Authors:  Helga Thorvaldsdóttir; James T Robinson; Jill P Mesirov
Journal:  Brief Bioinform       Date:  2012-04-19       Impact factor: 11.622

9.  NCBI Reference Sequences (RefSeq): current status, new features and genome annotation policy.

Authors:  Kim D Pruitt; Tatiana Tatusova; Garth R Brown; Donna R Maglott
Journal:  Nucleic Acids Res       Date:  2011-11-24       Impact factor: 16.971

10.  Epstein-Barr virus nuclear antigen 2 exerts its transactivating function through interaction with recombination signal binding protein RBP-J kappa, the homologue of Drosophila Suppressor of Hairless.

Authors:  U Zimber-Strobl; L J Strobl; C Meitinger; R Hinrichs; T Sakai; T Furukawa; T Honjo; G W Bornkamm
Journal:  EMBO J       Date:  1994-10-17       Impact factor: 11.598

View more
  66 in total

Review 1.  EBV Noncoding RNAs.

Authors:  Rebecca L Skalsky; Bryan R Cullen
Journal:  Curr Top Microbiol Immunol       Date:  2015       Impact factor: 4.291

2.  Genome-Wide Analysis of 18 Epstein-Barr Viruses Isolated from Primary Nasopharyngeal Carcinoma Biopsy Specimens.

Authors:  Chaofeng Tu; Zhaoyang Zeng; Peng Qi; Xiayu Li; Zhengyuan Yu; Can Guo; Fang Xiong; Bo Xiang; Ming Zhou; Zhaojian Gong; Qianjin Liao; Jianjun Yu; Yi He; Wenling Zhang; Xiaoling Li; Yong Li; Guiyuan Li; Wei Xiong
Journal:  J Virol       Date:  2017-08-10       Impact factor: 5.103

3.  Global bidirectional transcription of the Epstein-Barr virus genome during reactivation.

Authors:  Tina O'Grady; Subing Cao; Michael J Strong; Monica Concha; Xia Wang; Sandra Splinter Bondurant; Marie Adams; Melody Baddoo; Sudesh K Srivastav; Zhen Lin; Claire Fewell; Qinyan Yin; Erik K Flemington
Journal:  J Virol       Date:  2013-11-20       Impact factor: 5.103

4.  Molecular properties of the Epstein-Barr virus BFRF3 gene.

Authors:  Mingsheng Cai; Zhiyao Zhao; Wei Cui; Lin Yang; Junyi Zhu; Yalan Chen; Changling Ma; Zhuqing Yuan; Meili Li
Journal:  Virol Sin       Date:  2013-11-14       Impact factor: 4.327

5.  Latent Expression of the Epstein-Barr Virus (EBV)-Encoded Major Histocompatibility Complex Class I TAP Inhibitor, BNLF2a, in EBV-Positive Gastric Carcinomas.

Authors:  Michael J Strong; Thomas Laskow; Hani Nakhoul; Eugene Blanchard; Yaozhong Liu; Xia Wang; Melody Baddoo; Zhen Lin; Qinyan Yin; Erik K Flemington
Journal:  J Virol       Date:  2015-07-15       Impact factor: 5.103

6.  Structural and Functional Basis for an EBNA1 Hexameric Ring in Epstein-Barr Virus Episome Maintenance.

Authors:  Julianna S Deakyne; Kimberly A Malecka; Troy E Messick; Paul M Lieberman
Journal:  J Virol       Date:  2017-09-12       Impact factor: 5.103

7.  New Noncoding Lytic Transcripts Derived from the Epstein-Barr Virus Latency Origin of Replication, oriP, Are Hyperedited, Bind the Paraspeckle Protein, NONO/p54nrb, and Support Viral Lytic Transcription.

Authors:  Subing Cao; Walter Moss; Tina O'Grady; Monica Concha; Michael J Strong; Xia Wang; Yi Yu; Melody Baddoo; Kun Zhang; Claire Fewell; Zhen Lin; Yan Dong; Erik K Flemington
Journal:  J Virol       Date:  2015-04-29       Impact factor: 5.103

8.  Epstein-Barr virus and human herpesvirus 6 detection in a non-Hodgkin's diffuse large B-cell lymphoma cohort by using RNA sequencing.

Authors:  Michael J Strong; Tina O'Grady; Zhen Lin; Guorong Xu; Melody Baddoo; Chris Parsons; Kun Zhang; Christopher M Taylor; Erik K Flemington
Journal:  J Virol       Date:  2013-09-18       Impact factor: 5.103

9.  Epstein-Barr virus BALF3 has nuclease activity and mediates mature virion production during the lytic cycle.

Authors:  Shih-Hsin Chiu; Meng-Chuan Wu; Chung-Chun Wu; Yu-Ching Chen; Su-Fang Lin; John T-A Hsu; Chung-Shi Yang; Ching-Hwa Tsai; Kenzo Takada; Mei-Ru Chen; Jen-Yang Chen
Journal:  J Virol       Date:  2014-02-19       Impact factor: 5.103

10.  A Genome-Wide Epstein-Barr Virus Polyadenylation Map and Its Antisense RNA to EBNA.

Authors:  Vladimir Majerciak; Wenjing Yang; Jing Zheng; Jun Zhu; Zhi-Ming Zheng
Journal:  J Virol       Date:  2019-01-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.